The tumor-suppressive and potential therapeutic functions of miR-34a in epithelial carcinomas

Expert Opinion on Therapeutic Targets

Volumn 20, Issue 6, 2016, Pages 737-753

  Adams, Brian D ^a,b   Parsons, Christine ^a   Slack, Frank J ^b  

^a YALE UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Biomarker; breast cancer; cancer; lung; microRNA; miR 34; therapy; treatment resistance; tumor suppressor

Indexed keywords

ANTINEOPLASTIC AGENT; MICRORNA 34A; MICRORNA; MIRN34 MICRORNA, HUMAN;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CARCINOMA; CELL INVASION; CELL PROLIFERATION; COLORECTAL CANCER; GENETIC REGULATION; HUMAN; LIVER CANCER; LUNG CANCER; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; REVIEW; SOLID TUMOR; TISSUE DIFFERENTIATION; ANIMAL; DRUG RESISTANCE; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS, GLANDULAR AND EPITHELIAL; PATHOLOGY; TUMOR INVASION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; HUMANS; MICRORNAS; MOLECULAR TARGETED THERAPY; NEOPLASM INVASIVENESS; NEOPLASMS, GLANDULAR AND EPITHELIAL;

EID: 84949558870     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2016.1114102     Document Type: Review

References (103)

1. D.P.Bartel MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–297.
2. Z.Mourelatos, J.Dostie, S.Paushkin, et al. miRNPs: a novel class of ribonucleoproteins containing numerous microRNAs. Genes Dev. 2002;16:720–728.
3. R.Friedman, K.Farh. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009;19:92–105.
4. A.Bouchie. First microRNA mimic enters clinic. Nat Biotechnol. Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved. 2013;31:577.•• Discusses how MRX34 is the first-in-class miRNA replacement therapy for cancer.
5. H.Hermeking. The miR-34 family in cancer and apoptosis. Cell Death Differ. 2010;17:193–199.
6. R.Song, P.Walentek, N.Sponer, et al. miR-34/449 miRNAs are required for motile ciliogenesis by repressing cp110. Nature. 2014;510:115–120.
7. J.Wu, J.Bao, M.Kim, et al. Two miRNA clusters, miR-34b/c and miR-449, are essential for normal brain development, motile ciliogenesis, and spermatogenesis. Proc Natl Acad Sci USA. 2014;111:E2851–E2857.
8. J.Bao, D.Li, L.Wang, et al. MicroRNA-449 and microRNA-34b/c function redundantly in murine testes by targeting E2F transcription factor-retinoblastoma protein (E2F-pRb) pathway. J Biol Chem. 2012;287:21686–21698.
9. Y.Xiaojing, F.Min, J.Xia, et al. miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb-E2F1 activity through a feedback loop by targeting CDK6 and CDC25A. Genes Dev. 2009;23:2388–2393.
10. B.Marcet, B.Chevalier, G.Luxardi, et al. Control of vertebrate multiciliogenesis by miR-449 through direct repression of the Delta/Notch pathway. Nat Cell Biol. 2011;13:693–699.
11. T.Bou Kheir, E.Futoma-Kazmierczak, A.Jacobsen, et al. miR-449 inhibits cell proliferation and is down-regulated in gastric cancer. Mol Cancer. 2011;10:29.
12. V.Tarasov, P.Jung, B.Verdoodt, et al. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle. 2007;6:1586–1593.
13. G.T.Bommer, I.Gerin, Y.Feng, et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol. Elsevier. 2007;17:1298–1307.
14. N.Raver-Shapira, E.Marciano, E.Meiri, et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell. 2007;26:731–743.• Verified miR-34a as a direct transcriptional target of p53 and demonstrated the importance of miR-34a’s role in p53-mediated apoptosis.
15. L.He, X.He, S.W.Lowe, et al. microRNAs join the p53 network–another piece in the tumour-suppression puzzle. Nat Rev Cancer. 2007;7:819–822.
16. T.C.Chang, E.A.Wentzel, O.A.Kent, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell. 2007;26:745–752.
17. M.Kato, T.Paranjape, R.U.Müller, et al. The mir-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cells. Oncogene. 2009;28:2419–2424.
18. M.Yamakuchi, M.Ferlito, C.J.Lowenstein. miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci USA. 2008;105:13421–13426.
19. B.Kumar, A.Yadav, J.Lang, et al. Dysregulation of microRNA-34a expression in head and neck squamous cell carcinoma promotes tumor growth and tumor angiogenesis. PLoS One. 2012;7:e37601.
20. R.L.Stallings. MicroRNA involvement in the pathogenesis of neuroblastoma: potential for microRNA mediated therapeutics. Curr Pharm Des. 2009;15:456–462.
21. Y.Akao, S.Noguchi, A.Iio, et al. Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells. Cancer Lett. 2011;300:197–204.
22. S.Roy, E.Levi, A.P.N.Majumdar, et al. Expression of miR-34 is lost in colon cancer which can be re-expressed by a novel agent CDF. J Hematol Oncol. 2012;5:58.
23. G.Misso, M.Teresa, D.Martino, et al. Mir-34: a new weapon against cancer ? Mol Ther Nucleic Acids. 2014;3:e194.
24. O.Merkel, D.Asslaber, J.D.Piñón, et al. Interdependent regulation of p53 and miR-34a in chronic lymphocytic leukemia. Cell Cycle. 2010;9:2764–2768.• Unlike the majority of studies discussed in the review, these two studies report increased, rather than decreased, expression of miR-34a during tumorigenesis, which could indicate that although the p53 network is activated, it is subsequently overwhelmed.
25. Y.Fujita, K.Kojima, N.Hamada, et al. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun. 2008;377:114–119.
26. K.Kojima, Y.Fujita, Y.Nozawa, et al. MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate. 2010;70:1501–1512.
27. H.Siemens, R.Jackstadt, S.Hünten, et al. miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle. 2011;10:4256–4271.
28. M.Rokavec, M.G.Öner, H.Li, et al. IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J Clin Invest. 2014;124:1853–1867.
29. F.Navarro, D.Gutman, E.Meire, et al. miR-34a contributes to megakaryocytic differentiation of K562 cells independently of p53. Blood. 2009;114:2181–2192.
30. A.Ichimura, Y.Ruike, K.Terasawa, et al. MicroRNA-34a inhibits cell proliferation by repressing mitogen-activated protein kinase kinase 1 during megakaryocytic differentiation of K562 cells. Mol Pharmacol. 2010;77:1016–1024.
31. J.A.Pulikkan, P.S.Peramangalam, V.Dengler, et al. C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations. Blood. 2010;116:5638–5649.
32. F.Yang, Q.Li, Z.Gong, et al. MicroRNA-34a targets Bcl-2 and sensitizes human hepatocellular carcinoma cells to sorafenib treatment. Technol Cancer Res Treat. 2013;13:77–86.
33. J.F.Wiggins, L.Ruffino, K.Kelnar, et al. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res. 2010;70:5923–5930.
34. C.Corcoran, S.Rani, L.O’Driscoll. miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression. Prostate. 2014;74:1320–1334.
35. G.Zhao, J.Guo, D.Li, et al. MicroRNA-34a suppresses cell proliferation by targeting LMTK3 in human breast cancer MCF-7 cell line. DNA Cell Biol. 2013;00:1–9.
36. R.A.Boon, K.Iekushi, S.Lechner, et al. MicroRNA-34a regulates cardiac ageing and function. Nature. 2013;495:107–110.
37. E.Y.Park, E.Chang, E.J.Lee, et al. Targeting of miR34a-NOTCH1 axis reduced breast cancer stemness and chemoresistance. Cancer Res. 2014;74:7573–7582.
38. P.Bu, K.-Y.Chen, J.H.Chen, et al. A microRNA miR-34a-regulated bimodal switch targets Notch in colon cancer stem cells. Cell Stem Cell. 2013;12:602–615.
39. M.-Y.Wu, J.Fu, X.Xiao, et al. MiR-34a regulates therapy resistance by targeting HDAC1 and HDAC7 in breast cancer. Cancer Lett. 2014;354:311–319.
40. S.Yang, Y.Li, J.Gao, et al. MicroRNA-34 suppresses breast cancer invasion and metastasis by directly targeting Fra-1. Oncogene. 2012;32:4294–4303.
41. J.Wu, G.Wu, L.Lv, et al. MicroRNA-34a inhibits migration and invasion of colon cancer cells via targeting to Fra-1. Carcinogenesis. 2012;33:519–528.
42. D.Zhang, J.Zhou, M.Dong. Dysregulation of microRNA-34a expression in colorectal cancer inhibits the phosphorylation of FAK via VEGF. Dig Dis Sci. 2014;59:958–967.
43. C.Liu, K.Kelnar, B.Liu, et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med. 2011;17:211–215.
44. V.P.Tryndyak, S.A.Ross, F.A.Beland, et al. Down-regulation of the microRNAs miR-34a, miR-127, and miR-200b in rat liver during hepatocarcinogenesis induced by a methyl-deficient diet. Mol Carcinog. 2009;48:479–487.
45. V.J.Craig, S.B.Cogliatti, J.Imig, et al. Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1. Blood. 2011;117:6227–6236.
46. A.Hau, P.Ceppi, M.E.Peter. CD95 is part of a let-7/p53/miR-34 regulatory network. PLoS One. 2012;7:e49636.
47. C.P.Concepcion, Y.-C.Han, P.Mu, et al. Intact p53-dependent responses in miR-34-deficient mice. Grimes HL, editor. PLoS Genet. Public Library of Science; 2012; 8:e1002797.
48. M.Mraz, K.Malinova, J.Kotaskova, et al. miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities. Leukemia. 2009;23:1159–1163.
49. M.K.Dijkstra, K.Van Lom, D.Tielemans, et al. 17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation. Leukemia. 2009;23:625–627.
50. B.D.Adams, A.L.Kasinski, F.J.Slack. Aberrant regulation and function of microRNAs in cancer. Curr Biol. 2014;24:R762–R776.
51. X.J.Li, Z.J.Ren, J.H.Tang. MicroRNA-34a: a potential therapeutic target in human cancer. Cell Death Dis. 2014;5:e1327.
52. X.Wang, J.Li, K.Dong, et al. Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia. Cell Signal. 2015;27:443–452.
53. S.T.Jacob. Breast cancer. Introduction. Gene Expr. 2011;15:103.
54. C.Eichelser, D.Flesch-Janys, J.Chang-Claude, et al. Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression. Clin Chem. 2013;59:1489–1496.
55. P.Frères, C.Josse, N.Bovy, et al. Neoadjuvant chemotherapy in breast cancer patients induces miR-34a and miR-122 expression. J Cell Physiol. 2014;230:473–481.
56. A.Javeri, M.Ghaffarpour, M.F.Taha, et al. Downregulation of miR-34a in breast tumors is not associated with either p53 mutations or promoter hypermethylation while it correlates with metastasis. Med Oncol. 2013;30:413.
57. M.Mackiewicz, K.Huppi, J.J.Pitt, et al. Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA. Breast Cancer Res Treat. 2011;130:663–679.
58. B.D.Lehmann, J.A.Bauer, X.Chen, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. American Society for Clinical Investigation. 2011;121:2750–2767.
59. X.J.Li, M.H.Ji, S.L.Zhong, et al. MicroRNA-34a modulates chemosensitivity of breast cancer cells to adriamycin by targeting notch1. Arch Med Res. 2012;43:514–521.
60. X.Deng, M.Cao, J.Zhang, et al. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer. Biomaterials. 2014;35:4333–4344.
61. L.Kastl, I.Brown, A.C.Schofield. miRNA-34a is associated with docetaxel resistance in human breast cancer cells. Breast Cancer Res Treat. 2012;131:445–454.
62. L.Li, L.Yuan, J.Luo, et al. MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1. Clin Exp Med. 2013;13:109–117.
63. J.Zhao, K.Kelnar, A.G.Bader. In-depth analysis shows synergy between erlotinib and miR-34a. PLoS One. 2014;9:e89105.
64. C.Stahlhut, F.J.Slack. Combinatorial action of microRNAs let-7 and miR-34 effectively synergizes with erlotinib to suppress non-small cell lung cancer cell proliferation. Cell Cycle. 2015;14:2171–2180.
65. J.-Y.Zhou, X.Chen, J.Zhao, et al. MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET. Cancer Lett. 2014;351:265–271.
66. W.Xue, J.E.Dahlman, T.Tammela, et al. Small RNA combination therapy for lung cancer. Proc Natl Acad Sci USA. 2014;111:E3553–E3561.• Highlights the importance of considering the synergistic effects of miR-34a with other small RNAs as well as with traditional chemotherapeutics.
67. A.L.Kasinski, K.Kelnar, C.Stahlhut, et al. A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer. Oncogene. 2014;34:3547–3555.
68. J.Wu, G.Wu, L.Lv, et al. MicroRNA-34a inhibits migration and invasion of colon cancer cells via targeting to Fra-1. Carcinogenesis. 2012;33:519–528.
69. M.Nugent, N.Miller, M.J.Kerin. Circulating miR-34a levels are reduced in colorectal cancer. J Surg Oncol. 2012;106:947–952.
70. M.Wang, P.Zhang, Y.Li, et al. The quantitative analysis by stem-loop real-time PCR revealed the microRNA-34a, microRNA-155 and microRNA-200c overexpression in human colorectal cancer. Med Oncol. 2012;29:3113–3118.
71. M.Vogt, J.Munding, M.Grüner, et al. Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. Virchows Arch. 2011;458:313–322.
72. H.Siemens, J.Neumann, R.Jackstadt, et al. Detection of miR-34a promoter methylation in combination with elevated expression of c-Met and β-catenin predicts distant metastasis of colon cancer. Clin Cancer Res. 2013;19:710–720.
73. P.Dandawate, S.Padhye, A.Ahmad, et al. Novel strategies targeting cancer stem cells through phytochemicals and their analogs. Drug Deliv Transl Res. 2013;3:165–182.
74. Y.Akao, F.Khoo, M.Kumazaki, et al. Extracellular disposal of tumor-suppressor miRs-145 and −34a via microvesicles and 5-FU resistance of human colon cancer cells. Int J Mol Sci. 2014;15:1392–1401.
75. F.Meng, S.S.Glaser, H.Francis, et al. Epigenetic regulation of miR-34a expression in alcoholic liver injury. Am J Pathol. 2012;181:804–817.
76. H.Chen, Y.Sun, R.Dong, et al. Mir-34a is upregulated during liver regeneration in rats and is associated with the suppression of hepatocyte proliferation. PLoS One. 2011;6:e20238.
77. N.Li, H.Fu, Y.Tie, et al. miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett. 2009;275:44–53.
78. T.Sukata, K.Sumida, M.Kushida, et al. Circulating microRNAs, possible indicators of progress of rat hepatocarcinogenesis from early stages. Toxicol Lett. 2011;200:46–52.
79. J.Cheng, L.Zhou, Q.-F.Xie, et al. The impact of miR-34a on protein output in hepatocellular carcinoma HepG2 cells. Proteomics. 2010;10:1557–1572.
80. D.-W.Seol, Q.Chen, M.L.Smith, et al. Regulation of the c-met proto-oncogene promoter by p53. J Biol Chem. 1999;274:3565–3572.
81. R.S.Herbst, J.V.Heymach, S.M.Lippman. Lung cancer. N Engl J Med. 2008;359:1367–1380.
82. N.Bandi, E.Vassella. miR-34a and miR-15a/16 are co-regulated in non-small cell lung cancer and control cell cycle progression in a synergistic and Rb-dependent manner. Mol Cancer. 2011;10:55.
83. Y.Shi, C.Liu, X.Liu, et al. The microRNA miR-34a inhibits non-small cell lung cancer (NSCLC) growth and the CD44hi stem-like NSCLC cells. PLoS One. 2014;9:e90022.
84. E.Gallardo, A.Navarro, N.Viñolas, et al. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis. 2009;30:1903–1909.
85. Z.Wang, Z.Chen, Y.Gao, et al. DNA hypermethylation of microRNA-34b/c has prognostic value for stage I non-small cell lung cancer. Cancer Biol Ther. Landes Bioscience. 2011;11:490–496.
86. D.Lodygin, V.Tarasov, A.Epanchintsev, et al. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle. 2008;7:2591–2600.
87. W.Pao, V.A.Miller, K.A.Politi, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2:0225–0235.
88. P.Trang, J.F.Wiggins, C.L.Daige, et al. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther J Am Soc Gene Ther. Nature Publishing Group. 2011;19:1116–1122.
89. A.L.Kasinski, F.J.Slack. miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma. Cancer Res. 2012;72:5576–5587.
90. C.L.Daige, J.F.Wiggins, L.Priddy, et al. Systemic delivery of a miR-34a mimic as a potential therapeutic for liver cancer. Mol Cancer Ther. 2014;13:2352–2360.
91. H.Tazawa, N.Tsuchiya, M.Izumiya, et al. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci. 2007;104:15472–15477.
92. C.J.Cheng, R.Bahal, I.A.Babar, et al. MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature. 2015;518:107–110.
93. C.Sheridan, H.Kishimoto, R.K.Fuchs, et al. CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res. 2006;8:R59.
94. A.Jaggupilli, E.Elkord. Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clin. Dev. Immunol. 2012;2012:708036–708046.
95. J.Zhou, J.J.Rossi. Cell-type-specific, aptamer-functionalized agents for targeted disease therapy. Mol Ther Nucleic Acids. 2014;3:e169.
96. W.-M.W.-M.-M.Li, T.Bing, J.-Y.-Y.J.-Y.Wei, et al. Cell-SELEX-based selection of aptamers that recognize distinct targets on metastatic colorectal cancer cells. Biomaterials. 2014;35:6998–7007.• Demonstrate the potential of using aptamer targeting to achieve more efficient drug delivery and reduce off-target effects.
97. Y.Huang, Y.Qi, J.-Q.Du, et al. MicroRNA-34a regulates cardiac fibrosis after myocardial infarction by targeting Smad4. Expert Opin Ther Targets. 2014;18:1355–1365.• Highlights the negative consequences of overexpression of miR-34a in cardiac tissue and subsequent aberrant apoptosis of cardiomyocytes.
98. Z.Smit-McBride, K.I.Forward, A.T.Nguyen, et al. Age-dependent increase in miRNA-34a expression in the posterior pole of the mouse eye. Mol Vis. 2014;20:1569–1578.
99. P.Lovis, E.Roggli, D.R.Laybutt, et al. Alterations in microRNA expression contribute to fatty acid-induced pancreatic beta-cell dysfunction. Diabetes. 2008;57:2728–2736.
100. M.B.Backe, G.W.Novotny, D.P.Christensen, et al. Altering beta-cell number through stable alteration of miR-21 and miR-34a expression. Islets. 2014;6:e27754.
101. P.Jiang, R.Liu, Y.Zheng, et al. MiR-34a inhibits lipopolysaccharide-induced inflammatory response through targeting Notch1 in murine macrophages. Exp Cell Res. 2012;318:1175–1184.
102. A.G.Bader. miR-34 - a microRNA replacement therapy is headed to the clinic. Front Genet. 2012;3:120.
103. L.Li, X.Xie, J.Luo, et al. Targeted expression of miR-34a using the T-VISA system suppresses breast cancer cell growth and invasion. Mol Ther. 2012;20:2326–2334.